

<p align="center">U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</p> <p align="center">INFORMATION DISCLOSURE CITATION</p> <p align="center"><i>(Use several sheets if necessary)</i></p> <p align="right">Page 1 of 1</p>	<p>ATTY. DOCKET NO. MGH-028AUS</p>	<p>APPLICATION NO. 10/814,852</p>
	<p>APPLICANT Maurizio Fava et al.</p>	
	<p>FILING DATE March 31, 2004</p>	<p>GROUP 3626</p>

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)		
		HOFFMAN ET AL., Prospective Randomized Trial to Evaluate Two Delayed Granulocyte Colony Stimulating Factor Administration Schedules After High-Dose Cytarabine Therapy in Adult Patients With Acute Lymphoblastic Leukemia , Ann Hemotol 81; October 17, 2002, pp. 570-574.
		KRAEMER, Ph.D., et al., How Do Risk Factors Work Together? Mediators, Moderators, and Independent Overlapping and Proxy Risk Factors, American Journal of Psychiatry, June 2001, pp. 848-856.
		KRAVITZ, et al., Evidence-Based Medicine, Heterogeneity of Treatment Effects, and the Trouble with Averages, University of California, The Milbank Quarterly, Volume 82, No. 4, 2004, pp. 661-687.
		WILLIAM J. CARPENTER, JR., M.D., From Clinical Trial to Prescription, Arch Gen Psychiatry, Volume 59, March 2002, pp. 282-285.
		KRAEMER, Ph.D., et al., Mediators and Moderators of Treatment Effects in Randomized Clinical Trials, Arch Gen Psychiatry, Volume 59, October 2002, pp. 877-883.
Examiner		<p align="center">Date Considered:</p> <p><small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and considered. Include copy of this form with next communication to applicant.</small></p>

(132131-*-)